Progress in Analgesia by Volkow, Nora D.
Linda Chang, M.D.
Professor, Department of Medicine
John A. Burns School of Medicine
University of Hawaii
Honolulu, Hawaii
Hendree Jones, Ph.D.
Associate Professor of Behavioral Biology
Research Director, Center for Addiction and Pregnancy
Program Director, Cornerstone
Department of Psychiatry and Behavioral Sciences 
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Thomas R. Kosten, M.D.
Jay H. Waggoner Chair and Professor of Psychiatry and Neuroscience
Baylor College of Medicine
Houston, Texas
Patricia Molina, Ph.D.
Ashman Professor, Department of Physiology
Louisiana State University Health Sciences Center
New Orleans, Louisiana
Edward V. Nunes, M.D.
Professor of Clinical Psychiatry
Columbia University College of Physicians and Surgeons
New York, New York
James Sorenson, Ph.D.
Professor of Psychiatry
University of California, San Francisco
San Francisco General Hospital Medical Center
San Francisco, California
Claire E. Sterk, Ph.D.
Senior Vice Provost for Academic Planning and Faculty Development
Charles Howard Candler Professor of Public Health
Emory University
Atlanta, Georgia
Betty Tai, Ph.D.
Director, Center for the Clinical Trials Network
National Institute on Drug Abuse
Bethesda, Maryland
Nancy Waite-O’Brien, Ph.D.
Consultant
The Betty Ford Center
Rancho Mirage, California
ADDICTION SCIENCE & CLINICAL PRACTICE EDITORIAL
BOARD A Note From NIDA’s Director
Progress in Analgesia
T
he lead article in this issue of Addiction Science &
Clinical Practice focuses on the blessing and curse
of opioids. Drs. Savage, Kirsh, and Passik offer invalu-
able practical advice, useful to both substance abuse cli-
nicians and pain specialists, on negotiating the difficult
clinical issues that arise as a result of opioids’ gift of
powerful analgesia and their bane of addiction.
While supporting these authors’ research to maxi-
mize the safe and effective use of opioids, NIDA is also
fostering the development of new medications that may
relieve severe pain without risk of addiction. Some
approaches have already shown promise in laboratory
studies with animals. They include inhibiting the neu-
ron-regulating cells called glia and creating new types of
compound molecules that simultaneously and selec-
tively interact with multiple receptors. Some of the com-
pounds under study suppress pain many times more
powerfully than morphine.
Success in these efforts will markedly advance
NIDA’s mission to reduce the prevalence and the health
and social consequences of drug abuse and addiction.
Opioid abuse will not vanish, because, despite recent
increases in the prevalence of prescription opioid abuse,
many new addictions and new treatment presentations
still involve illegal opioids. However, the incidence of
prescription opioid addiction will likely fall. Hospitals
and pharmacies will be able to stock fewer addictive
medications, making fewer available for diversion. The
issues Dr. Savage and coauthors discuss so authorita-
tively will not vanish, but many decisions in the treat-
ment of both pain and substance abuse should become
simpler.
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